

Frederick L Locke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1947000/publications.pdf>

Version: 2024-02-01

116
papers

15,023
citations

126858

33
h-index

40954

93
g-index

121
all docs

121
docs citations

121
times ranked

10066
citing authors

#	ARTICLE	IF	CITATIONS
1	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	13.9	3,865
2	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 625-638.	2.0	1,741
3	Chimeric antigen receptor T-cell therapy " assessment and management of toxicities. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 47-62.	12.5	1,659
4	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1 "2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.	5.1	1,467
5	KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2020, 382, 1331-1342.	13.9	1,067
6	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 640-654.	13.9	586
7	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. <i>Molecular Therapy</i> , 2017, 25, 285-295.	3.7	498
8	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2020, 38, 3119-3128.	0.8	481
9	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 5414-5424.	2.5	263
10	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4898-4911.	2.5	238
11	Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). <i>Journal of the American College of Cardiology</i> , 2019, 74, 3099-3108.	1.2	225
12	CAR-HEMATOTOX: a model for CAR T-cell "related hematologic toxicity in relapsed/refractory large B-cell lymphoma. <i>Blood</i> , 2021, 138, 2499-2513.	0.6	160
13	Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 978-986.	1.7	141
14	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
15	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2621-2633.	0.6	137
16	High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3268-3276.	2.5	134
17	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 218-218.	12.5	114
18	Efficacy and safety of <sc>CD19</sc> "directed <sc>CAR " </sc> cell therapies in patients with relapsed/refractory aggressive B "cell lymphomas: Observations from the <sc>JULIET</sc>, <sc>ZUMA</sc> "1, and <sc>TRANSCEND</sc> trials. <i>American Journal of Hematology</i> , 2021, 96, 1295-1312.	2.0	107

#	ARTICLE	IF	CITATIONS
19	Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1012-1021.	0.4	105
20	Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. <i>Blood</i> , 2020, 135, 2106-2109.	0.6	90
21	CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Blood</i> , 2021, 138, 1081-1085.	0.6	84
22	A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2012, 97, 1882-1889.	1.7	82
23	Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 555-567.	0.8	82
24	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. <i>Blood</i> , 2018, 132, 91-91.	0.6	81
25	Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3034-3043.	0.8	76
26	Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. <i>BioDrugs</i> , 2019, 33, 45-60.	2.2	61
27	Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 581.e1-581.e8.	0.6	61
28	Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. <i>Blood Advances</i> , 2020, 4, 1432-1439.	2.5	54
29	CAR T-Cell Therapy in Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1065-1065.	13.9	53
30	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. <i>Blood</i> , 2022, 139, 1330-1339.	0.6	52
31	The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. , 2022, 10, e004475.		50
32	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. <i>Blood</i> , 2021, 137, 1832-1835.	0.6	48
33	CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel. <i>Blood</i> , 2019, 134, 203-203.	0.6	48
34	Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. <i>Clinical Cancer Research</i> , 2020, 26, 4823-4831.	3.2	47
35	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4149-4155.	2.5	42
36	Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1581-1588.	2.0	40

#	ARTICLE	IF	CITATIONS
37	CAR T cell therapy for B-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 135-146.	0.7	39
38	Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma. <i>JAMA Oncology</i> , 2020, 6, 281.	3.4	36
39	Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. <i>British Journal of Haematology</i> , 2019, 187, e35-e38.	1.2	35
40	IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2017, 102, 948-957.	1.7	33
41	4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. , 2021, 9, e003354.		32
42	Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. <i>Blood Advances</i> , 2020, 4, 1440-1447.	2.5	29
43	Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1145-1154.	0.4	29
44	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	2.6	29
45	A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. <i>Blood</i> , 2016, 128, 998-998.	0.6	26
46	<i>In vivo</i> IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2018, 103, 531-539.	1.7	25
47	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. <i>Blood Advances</i> , 2022, 6, 486-494.	2.5	25
48	Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 458-468.	1.0	23
49	Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4086-4090.	2.5	22
50	The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2021, 288, 20210229.	1.2	22
51	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	1.3	21
52	Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 970-977.	1.7	19
53	Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 2887.	2.2	19
54	Cutting Edge: Engineering Active IKK ² in T Cells Drives Tumor Rejection. <i>Journal of Immunology</i> , 2016, 196, 2933-2938.	0.4	18

#	ARTICLE	IF	CITATIONS
55	Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e35-e39.	0.2	18
56	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
57	Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). <i>Cancer Research</i> , 2017, 77, CT019-CT019.	0.4	17
58	A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 509-514.	1.1	16
59	Merkel Cell Carcinoma and Immunosuppression: What We Still Need to Know. <i>Journal of the National Cancer Institute</i> , 2015, 107, dju422-dju422.	3.0	15
60	Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2014, 38, 1165-1172.	0.4	14
61	Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial Results. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1074-1082.	2.0	14
62	Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 659-661.	1.4	14
63	Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 305.e1-305.e9.	0.6	14
64	Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. <i>Cancer Medicine</i> , 2021, 10, 1936-1943.	1.3	13
65	Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1087-1093.	2.0	12
66	Conditional Deletion of PTEN in Peripheral T Cells Augments TCR-Mediated Activation but Does Not Abrogate CD28 Dependency or Prevent Anergy Induction. <i>Journal of Immunology</i> , 2013, 191, 1677-1685.	0.4	12
67	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 885-907.	0.6	12
68	CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 405-411.	2.0	11
69	Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 2897-2903.	1.3	10
70	Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 401.e1-401.e7.	0.6	10
71	Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015, 126, 3991-3991.	0.6	9
72	Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma. , 2015, 3, 20.		8

#	ARTICLE	IF	CITATIONS
73	Myeloablative Intravenous Pharmacokinetically Targeted Busulfan Plus Fludarabine As Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 335-340.	0.2	8
74	Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study. <i>Oncology and Therapy</i> , 2022, 10, 123-141.	1.0	8
75	Quality of life in caregivers of patients receiving chimeric antigen receptor T cell therapy. <i>Psycho-Oncology</i> , 2021, 30, 1294-1301.	1.0	6
76	Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. <i>Journal of Medical Economics</i> , 2022, 25, 541-551.	1.0	6
77	Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 753-759.	0.2	6
78	Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization. <i>Cancers</i> , 2022, 14, 2742.	1.7	6
79	Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. <i>Blood Advances</i> , 2022, 6, 3970-3973.	2.5	6
80	Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap. , 2017, 5, 59.		5
81	Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 400-405.	2.0	5
82	Beat pediatric ALL MRD: CD28 CAR T and transplant. <i>Blood</i> , 2019, 134, 2333-2335.	0.6	5
83	Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 242.e1-242.e6.	0.6	5
84	Abstract CT020: Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19). , 2017, , .		5
85	Patient-Reported and Neurocognitive Outcomes in Patients Treated with Axicabtagene Ciloleucel. <i>Blood</i> , 2018, 132, 2289-2289.	0.6	5
86	A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 259-269.	2.5	5
87	What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 350-353.	0.9	4
88	Immunotherapy strategies for multiple myeloma: the present and the future. <i>Immunotherapy</i> , 2013, 5, 1005-1020.	1.0	4
89	Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 768.e1-768.e6.	0.6	4
90	Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma" <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e335-e336.	2.0	4

#	ARTICLE	IF	CITATIONS
91	What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?. Hematology American Society of Hematology Education Program, 2012, 2012, 350-3.	0.9	4
92	Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. Transplantation and Cellular Therapy, 2022, 28, 487.e1-487.e7.	0.6	4
93	A Phase I/II Trial Evaluating The Use Of a Histone Deacetylase Inhibitor Panobinostat (LBH589) In Addition To Glucocorticoids In Patients With Acute Graft-Versus-Host Disease. Blood, 2013, 122, 3308-3308.	0.6	3
94	A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right Direction. Molecular Therapy, 2017, 25, 2241-2243.	3.7	2
95	Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). Blood, 2015, 126, 2730-2730.	0.6	2
96	Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. American Journal of Hematology, 2019, 94, E245-E247.	2.0	1
97	ABCL-289: Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S388.	0.2	1
98	Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd. Blood, 2011, 118, 323-323.	0.6	1
99	The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation. Blood, 2012, 120, 4195-4195.	0.6	1
100	Chimeric Antigen Receptor T Cell Therapy Delivers Response in Lymphoma Progressing after Allogeneic Transplantation, but is the Sequence Optimal?. Biology of Blood and Marrow Transplantation, 2020, 26, e211-e212.	2.0	0
101	Antibodies Against Vaccine-preventable Infections After CD19 or BCMA CAR T-cell Therapy. , 2021, 18, .		0
102	IFN Signaling and Myeloid Cells in the Setting of CAR T: A Central Role for the Induction of Endogenous Anti-tumor Immunity. , 2021, 18, .		0
103	Seeing the light: CAR T cell targeting of lambda-restricted B cell lymphomas. Clinical Cancer Research, 2021, 27, clincanres.1450.2021.	3.2	0
104	Belumosudil: A Rising Star for the Management of Chronic Graft-Versus-Host Disease and the First FDA-Approved ROCK2 Inhibitor. , 2021, 18, .		0
105	Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PBÂ±R) Using a Novel Principle of CD4-Guided Immune Suppression. Blood, 2011, 118, 3022-3022.	0.6	0
106	A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. Blood, 2011, 118, 496-496.	0.6	0
107	Gene Deletions of 17p or 11q Are Independent Predictors of Decreased Progression-Free Survival and Overall Survival Following Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. Blood, 2012, 120, 2007-2007.	0.6	0
108	Survival Advantage of Cell Therapy Over Cytotoxic Therapy Alone in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 1994-1994.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine. Blood, 2013, 122, 2152-2152.	0.6	0
110	Sequential Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide Is a Safe and Effective Regimen for the Treatment of Previously Treated and Untreated CLL/SLL: The Hilo Trial. Blood, 2015, 126, 2941-2941.	0.6	0
111	Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies. Blood, 2015, 126, 5524-5524.	0.6	0
112	Hypo-Albuminemia at Day+90 after Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies Independently Predicts for Inferior Overall Survival and Higher Non-Relapse Mortality. Blood, 2015, 126, 4407-4407.	0.6	0
113	Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia. Blood, 2018, 132, 3150-3150.	0.6	0
114	Ruxolitinib: A Long-Awaited Standard for Steroid Refractory Acute Graft-Versus-Host Disease. , 2020, 17, .		0
115	Solid Tumor TIL Therapy Is Infiltrating Multiple Centers With Lympho-â€œsightsâ€œ-Set on Becoming Standard of Care. , 2022, 19, .		0
116	Transverse myelitis after anti-â€œCD19 directed CAR T cell therapy for relapsed large B cell lymphoma. EJHaem, 2022, 3, 223-227.	0.4	0